The UK National Institute for Health and Care Excellence (NICE) has issued a Medtech Innovation Briefing (MIB) on Hemcheck’s novel point of care hemolysis detection technology. The briefing reports that the technology is novel and that there can be several benefits for patients and the system, such as reducing delays to correct and final blood results, speeding up clinical decisions and avoiding false conclusions related to blood gas analysis.
NICE Medtech Innovation Briefings are designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. The information provided includes a description of the technology, how it is used and its potential role in the treatment pathway. A MIB also includes a review of relevant published evidence and the likely costs of using the technologies, but they are not NICE guidance and do not make any recommendations on the value of using the technologies. This is the 22nd MIB publicised this year by NICE.
-It is positive that NICE decided to select our technology for a MIB and that it is now publicised. It will further improve the credibility in our dialogues with UK stakeholders. We are now working on trying to set up trials in the UK to provide local evidence, which the UK market requires, says Joen Averstad, CEO of Hemcheck.
To review the MIB, please visit
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care in the UK. NICE’s role is to improve outcomes for people using the NHS and other public health and social care services.
Read more at https://www.nice.org.uk
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.